NEW YORK, May 27 (GenomeWeb News) - PamGene has exclusively licensed its microarray technology to Innogenetics for development of multiple-parameter nucleic acid-and protein diagnostics in the area of infectious diseases, genetic testing and neurodegeneration, the companies said today.
Under the agreement, Innoenetics of Gent, Belgium will be able to develop tests in these areas for use on PamGene's PamStation 12 instruments. The license may be extended to oncology applications. The parties did not disclose the exact financial terms of the agreement, but said it includes an upfront payment as well as milestone fees when tests are launched on the market, and royalties on sales of these tests.
Innogenetics said it selected PamGene because PamGene's technology will allow the company to develop tests that can assess 400 different parameters in a single sample run-ten times the number of parameters the company is currently able to assess per run with its existing technology.
The companies said the first set of tests is expected to "reach the market" in 2006.
PamGene, of Den Bosch, The Netherlands, markets a three-dimensional microarary technology. The PamChip standard or custom microarrays are built to the format of a 1x3-inch microscope glass slide. The slips are made of plastic laminate sandwiching a porous metal oxide that contains four array areas, on which up to 400 three-dimensional spots of oligonucleotides, proteins, peptides, or DNA-fragments are spotted by ink jet. Instead of being contained on a surface, these molecules cleave to the insides of capillaries within the metal oxide, allowing hybridization while the sample flows through the capillaries.
PamGene raised €10 Million last July in a second fundraising round.